These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28650589)

  • 1. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
    Hoy JF; Grund B; Roediger M; Schwartz AV; Shepherd J; Avihingsanon A; Badal-Faesen S; de Wit S; Jacoby S; La Rosa A; Pujari S; Schechter M; White D; Engen NW; Ensrud K; Aagaard PD; Carr A;
    J Bone Miner Res; 2017 Sep; 32(9):1945-1955. PubMed ID: 28650589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy.
    Carr A; Grund B; Schwartz AV; Avihingsanon A; Badal-Faesen S; Bernadino JI; Estrada V; La Rosa A; Mallon P; Pujari S; White D; Wyman Engen N; Ensrud K; Hoy JF;
    HIV Med; 2020 Jan; 21(1):64-70. PubMed ID: 31642586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous antiretroviral therapy decreases bone mineral density.
    Grund B; Peng G; Gibert CL; Hoy JF; Isaksson RL; Shlay JC; Martinez E; Reiss P; Visnegarwala F; Carr AD;
    AIDS; 2009 Jul; 23(12):1519-29. PubMed ID: 19531929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Carr A; Grund B; Neuhaus J; Schwartz A; Bernardino JI; White D; Badel-Faesen S; Avihingsanon A; Ensrud K; Hoy J;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):137-46. PubMed ID: 25711332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
    Assoumou L; Katlama C; Viard JP; Bentata M; Simon A; Roux C; Kolta S; Costagliola D; Rozenberg S;
    AIDS; 2013 Sep; 27(15):2425-30. PubMed ID: 24029735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
    Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
    HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.
    Grant PM; Kitch D; McComsey GA; Dube MP; Haubrich R; Huang J; Riddler S; Tebas P; Zolopa AR; Collier AC; Brown TT
    Clin Infect Dis; 2013 Nov; 57(10):1483-8. PubMed ID: 23943825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men.
    Erlandson KM; Lake JE; Sim M; Falutz J; Prado CM; Domingues da Silva AR; Brown TT; Guaraldi G
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):288-294. PubMed ID: 29140875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.
    Overton ET; Chan ES; Brown TT; Tebas P; McComsey GA; Melbourne KM; Napoli A; Hardin WR; Ribaudo HJ; Yin MT
    Ann Intern Med; 2015 Jun; 162(12):815-24. PubMed ID: 26075752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years.
    Kwak MK; Lee EJ; Park JW; Park SY; Kim B-; Kim TH; Suh K; Koh J-; Lee SH; Byun D-
    Osteoporos Int; 2019 Jul; 30(7):1501-1510. PubMed ID: 30915506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term trabecular bone score and bone mineral density changes in Chinese antiretroviral-treated HIV-infected individuals.
    Guan W; Pan W; Yu W; Cao W; Lin Q; Zhang Z; Song X; Li Y; Tian J; Xu Y; Li T; Hsieh E
    Arch Osteoporos; 2021 Feb; 16(1):41. PubMed ID: 33624129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study.
    Jacobson DL; Spiegelman D; Knox TK; Wilson IB
    J Acquir Immune Defic Syndr; 2008 Nov; 49(3):298-308. PubMed ID: 18845956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.
    Erlandson KM; Kitch D; Tierney C; Sax PE; Daar ES; Tebas P; Melbourne K; Ha B; Jahed NC; McComsey GA
    AIDS; 2013 Aug; 27(13):2069-79. PubMed ID: 24384588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
    Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
    Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.
    Kalayjian RC; Albert JM; Cremers S; Gupta SK; McComsey GA; Klingman KL; Fichtenbaum CJ; Brown TT; Taiwo BO;
    AIDS; 2018 Nov; 32(17):2517-2524. PubMed ID: 30134291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
    Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
    AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.
    Dave JA; Cohen K; Micklesfield LK; Maartens G; Levitt NS
    PLoS One; 2015; 10(12):e0144286. PubMed ID: 26633015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.
    Hoy J; Grund B; Roediger M; Ensrud KE; Brar I; Colebunders R; Castro ND; Johnson M; Sharma A; Carr A;
    J Bone Miner Res; 2013 Jun; 28(6):1264-74. PubMed ID: 23299909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
    AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
    McComsey GA; Lupo S; Parks D; Poggio MC; De Wet J; Kahl LP; Angelis K; Wynne B; Vandermeulen K; Gartland M; Cupo M; Aboud M;
    AIDS; 2018 Feb; 32(4):477-485. PubMed ID: 29239893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.